Mayflower Financial Advisors LLC Takes $317,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mayflower Financial Advisors LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 3,427 shares of the biopharmaceutical company’s stock, valued at approximately $317,000.

Other hedge funds also recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences during the third quarter valued at $25,000. Valued Wealth Advisors LLC boosted its position in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the period. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the 4th quarter worth about $29,000. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences during the second quarter worth approximately $33,000. Finally, Quarry LP bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $43,000. 83.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

GILD has been the topic of several research analyst reports. The Goldman Sachs Group increased their price objective on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday. Wolfe Research initiated coverage on shares of Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target for the company. Finally, Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target for the company. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $98.39.

Gilead Sciences Price Performance

Shares of GILD opened at $95.59 on Thursday. The company’s fifty day moving average price is $92.00 and its 200-day moving average price is $85.44. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The firm has a market capitalization of $119.13 billion, a PE ratio of 1,062.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.29 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at $12,886,126.44. This represents a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 456,234 shares of company stock worth $42,130,461. 0.16% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.